Author’s response to reviews

Title: Plasma expression of miRNA-21, -214, -34a, and -200a in patients with persistent HPV infections and cervical lesions

Authors:
Hongyun WANG (hongyunwangcn@126.com)
Dandan ZHANG (egg81811@163.com)
Qing CHEN (964565749@qq.com)
Ying Hong (hongying@nju.edu.cn)

Version: 4 Date: 17 Jul 2019

Author’s response to reviews:

Catherine Rice
BMC Cancer
July 17, 2019
Dear Catherine,

We would like to thank the editors for their hard work. We have significantly revised our manuscript, which is now titled “Plasma expression of miRNA-21, -214, -34a, and -200a in patients with persistent HPV infection and cervical lesions”. We would like to submit our revised manuscript for consideration for publication as a research article in BMC Cancer.

Please find our point-by-point responses to the comments of the reviewers below. The revised manuscript and the point-by-point response letter have been submitted. Our revised manuscript accurately shows the amendments to the manuscript text, and the specific page numbers and line numbers associated with the content changes are provided in the response letter for easy review.

We confirm that this paper has not been published elsewhere in whole or in part and does not contain any individual person’s data. All authors have read and approved the content and have agreed to submit the manuscript for consideration for publication in this journal. The authors have no conflicts of interest to declare.

I hope that, with your help, the revised article can be published.

I look forward to hearing from you soon.

Yours sincerely,
Ying Hong,
Professor,
Chief Doctor

FORMATTING CHANGES:

1. Figure legends must be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure or table, the following information should be provided: Figure or table number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure or table (maximum 15 words); detailed legend, up to 300 words.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have previously been published elsewhere.

Response
The editor’s comment is correct. We have modified the text as follows (Methods, line 16-17, page 5; Table 1., line 1, page 1):

In table 1 combine 42 normal controls, 31 persistent HPV and 19 CIN1 to 92 CIN1-, and 54 CIN2 + 71 CIN3 + 15 cancer to 140 CIN2+.

Table 1. Characteristics of CIN1- and CIN2+ patients

(Results, line 7-11, page 9; Table 3., line 1, page 1):

In table 3 combine 42 normal controls, 31 persistent HPV and 19 CIN1 to 92 CIN1-, and 54 CIN2 + 71 CIN3 + 15 cancer to 140 CIN2+.

Plasma miRNA levels of CIN1- is significantly different from that of CIN2+; p<0.01 (miRNA21, t=4.34, p=0.000; miRNA214, t=4.18, p=0.0001; miRNA200a, t=3.67, p=0.0002; miRNA, t=2.98, p=0.0017).

Table 3 Comparison of plasma miRNA levels in patients with cervical lesions of different grades

(Results, line 14-15, page 9; Table 4., line 1, page 1):

Table 4 Comparison of cervical tissue miRNA levels in patients with cervical lesions of different grades

(Results, line 32-33, page 9; Figure 1., line 1, page 1):

Figure 1 Comparison of ROC Curves for Expression of MiRNA in Plasma between CIN1- and CIN2+

(Results, line 3-4, page 10; Figure 2., line 1, page 1):

Figure 2 Comparison of ROC Curves for Expression of MiRNA in Plasma between CIN1- and CIN2+